<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769665</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-08-15</org_study_id>
    <nct_id>NCT00769665</nct_id>
  </id_info>
  <brief_title>A 2-week Clinical Comparison of SYSTANEÂ® Ultra to Sensitive Eyes Rewetting Drops in Contact Lens Wearing Patients.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety with the use of Systane Ultra in contact lens wearers. A comparison to a&#xD;
      currently marketed contact lens rewetting drop will be included as a control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events and Visual Acuity</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">47</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Systane Ultra</arm_group_label>
    <description>Systane Ultra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sensitive Eyes</arm_group_label>
    <description>Sensitive Eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systane Ultra</intervention_name>
    <description>Re-wetting ocular eye drop</description>
    <arm_group_label>Systane Ultra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sensitive Eyes Rewetting Drops</intervention_name>
    <description>Re-wetting ocular eye drop</description>
    <arm_group_label>Sensitive Eyes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        community sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be between 18 and 65 years of age.&#xD;
&#xD;
          -  Provide written Informed Consent.&#xD;
&#xD;
          -  Must be wearing a planned replacement soft lens in a 2 week or monthly replacement&#xD;
             modality, or a Rigid Gas Permeable (RGP) contact Lens&#xD;
&#xD;
          -  Must have best corrected distance visual acuity, with contact lenses, of 20/30 or&#xD;
             better in each eye.&#xD;
&#xD;
          -  Sodium fluorescein (NaFl) corneal staining score sum of &lt; 2 in both eyes (NEI scoring&#xD;
             system).&#xD;
&#xD;
          -  Must be willing to maintain pre-enrollment systemic medication regimens during the&#xD;
             study.&#xD;
&#xD;
          -  Must be available for study visits and to fill out study questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has modified their systemic medications within 30 days prior to enrollment.&#xD;
&#xD;
          -  Has a history of allergy to any study product ingredients&#xD;
&#xD;
          -  Is unwilling or unable to meet the study visit timeline.&#xD;
&#xD;
          -  Has any active corneal, eyelid or other anterior segment inflammation or infection,&#xD;
             which, in the opinion of the Investigator, would adversely affect successful contact&#xD;
             lens wear.&#xD;
&#xD;
          -  Is currently using any topical eye medications (not including rewetting drops,&#xD;
             artificial tear products or Restasis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>re-wetting drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

